Company:  OMEROS CORP (OMER)
Form Type:  10-K
Filing Date:  3/18/2013 
CIK:  0001285819 
Address:  201 ELLIOTT AVENUE WEST 
City, State, Zip:  SEATTLE, Washington 98119 
Telephone:  206-676-5000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$12.09  
Change: 
0.24 (2.03%)  
Trade Time: 
Apr 24  
Market Cap: 
$403.84M
Description of Business
We are a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Our most clinically advanced product, Omidria� for lens replacement surgery, is derived from our proprietary PharmacoSurgery� platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Our PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. In addition to Omidria, we have six other clinical-stage development programs in our pipeline.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS
        NAME AND TITLE
      ITEM 1A. RISK FACTORS
      ITEM 1B. UNRESOLVED STAFF COMMENTS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
      ITEM 4. MINE SAFETY DISCLOSURES
    PART II
      ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Results of Operations
        Liquidity and Capital Resources
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A. CONTROLS AND PROCEDURES
      REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
      ITEM 9B. OTHER INFORMATION
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
      ITEM 11. EXECUTIVE COMPENSATION
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND ...
      ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
    PART IV
      ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
    SIGNATURES
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    BALANCE SHEET
    INCOME STATEMENT
    STOCKHOLDERS EQUITY
    CASH FLOW
    NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
      BALANCE SHEET
    EXHIBIT INDEX
  EXHIBIT 10.18
  EXHIBIT 10.28
  EXHIBIT 10.32
  EXHIBIT 10.39
  EXHIBIT 10.41
  EXHIBIT 10.42
  EXHIBIT 10.43
  EXHIBIT 12.1
    RATIO COMPUTATION
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE
  EXHIBIT 31.2
    CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE
  EXHIBIT 32.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 ...
  EXHIBIT 32.2
    CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 ...
BROKERAGE PARTNERS